n.a. (VPHM)

49.96
0.01 0.02
NASDAQ
Prev Close 49.97
Open 49.98
Day Low/High 49.96 / 50.01
52 Wk Low/High 0.00 / 0.00
Volume 4.78M
Exchange NASDAQ
Shares Outstanding 65.97M
Market Cap 3.30B
Div & Yield N.A. (N.A)

Latest News

VIROPHARMA, INC. INVESTOR ALERT: The Law Offices Of Vincent Wong Investigates The Sale Of ViroPharma, Inc. To Shire PLC -- VPHM

VIROPHARMA, INC. INVESTOR ALERT: The Law Offices Of Vincent Wong Investigates The Sale Of ViroPharma, Inc. To Shire PLC -- VPHM

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of ViroPharma, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of ViroPharma, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of ViroPharma, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ViroPharma, Inc.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of ViroPharma Incorporated Stockholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of ViroPharma Incorporated Stockholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of ViroPharma Incorporated (“ViroPharma” or the “Company”) (NASDAQ:VPHM) concerning the proposed acquisition of the...

VIROPHARMA, INC. INVESTOR ALERT: The Law Offices Of Vincent Wong Investigates The Sale Of ViroPharma, Inc. To Shire PLC -- VPHM

VIROPHARMA, INC. INVESTOR ALERT: The Law Offices Of Vincent Wong Investigates The Sale Of ViroPharma, Inc. To Shire PLC -- VPHM

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of ViroPharma, Inc.

VIROPHARMA INCORPORATED INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of ViroPharma Inc. (VPHM) Over The Proposed Sale Of The Company To Shire (SHPG)

VIROPHARMA INCORPORATED INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of ViroPharma Inc. (VPHM) Over The Proposed Sale Of The Company To Shire (SHPG)

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ViroPharma Inc.

Market Up on Deals, Results

Market Up on Deals, Results

Markets edged higher as some stocks jumped on deal making, with key retailer results to be closely watched this week.

ViroPharma Larger Than S&P 500 Component JDS Uniphase

ViroPharma Larger Than S&P 500 Component JDS Uniphase

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component ViroPharma Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example JDS Uniphase Corp , according to The Online Investor.

SHAREHOLDER ALERT: Law Firm Brower Piven Announces Investigation Of Possible Breaches Of Fiduciary Duty By Directors Of ViroPharma Incorporated In Connection With Proposed Buyout

SHAREHOLDER ALERT: Law Firm Brower Piven Announces Investigation Of Possible Breaches Of Fiduciary Duty By Directors Of ViroPharma Incorporated In Connection With Proposed Buyout

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of ViroPharma Incorporated ...

Finkelstein Thompson LLP Announces Investigation Of ViroPharma Inc. Buyout Proposal

Finkelstein Thompson LLP Announces Investigation Of ViroPharma Inc. Buyout Proposal

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of ViroPharma Inc.

Shire Deal Just The Start

Shire Deal Just The Start

Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group.

ViroPharma Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Shire

ViroPharma Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Shire

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of ViroPharma...

VIROPHARMA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of ViroPharma Inc. (VPHM) Over The Proposed Sale Of The Company To Shire (SHPG) In A Cash Deal

VIROPHARMA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of ViroPharma Inc. (VPHM) Over The Proposed Sale Of The Company To Shire (SHPG) In A Cash Deal

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ViroPharma Inc.

Law Firm Brower Piven Announces Investigation Of ViroPharma Incorporated Proposed Buyout

Law Firm Brower Piven Announces Investigation Of ViroPharma Incorporated Proposed Buyout

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of ViroPharma Incorporated ...

Upbeat China Data Kickstarts Week

Upbeat China Data Kickstarts Week

Upbeat economic data from China prints ahead of the week's trading, while Viropharma and Transocean attract investors' attention.

Today's Pre-Market Mover With Heavy Volume: ViroPharma (VPHM)

Today's Pre-Market Mover With Heavy Volume: ViroPharma (VPHM)

Trade-Ideas LLC identified ViroPharma (VPHM) as a pre-market mover with heavy volume candidate

Shire Buying Viropharma for $4.2B to Bolster Rare Disease Unit

Shire Buying Viropharma for $4.2B to Bolster Rare Disease Unit

Shire's acquisition centers around Viropharma's Cinryze, which treats hereditary angioedema.

The Deal: Shire to Spend $4.2 Billion on ViroPharma

The Deal: Shire to Spend $4.2 Billion on ViroPharma

The target's main product, a preventative treatment for hereditary angiodema, complements the buyer's existing Firazyr treatment, which is used during attacks of the skin swelling disease.

Nov. 11 Premarket Briefing: 10 Things You Should Know

Nov. 11 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are flat; as many as 10,000 feared dead from Philippines typhoon; Apple reportedly designing curved iPhones; Shire to buy ViroPharma.

The Deal: Overseas Stocks Trade Mixed; Nikkei Rises 1.3%

The Deal: Overseas Stocks Trade Mixed; Nikkei Rises 1.3%

Overseas stocks are mixed Monday as the devastating typhoon Haiyan takes its toll on some Asian indices.

See How ViroPharma Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How ViroPharma Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that ViroPharma Inc. is the #47 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.

Interesting VPHM Put And Call Options For December 21st

Interesting VPHM Put And Call Options For December 21st

Investors in ViroPharma Inc. saw new options begin trading this week, for the December 21st expiration.

Short Interest Increases 11% For VPHM

Short Interest Increases 11% For VPHM

The most recent short interest data has been released by the NASDAQ for the 09/30/2013 settlement date, which shows a 1,016,702 share increase in total short interest for ViroPharma Inc. , to 10,360,380, an increase of 10.88% since 09/13/2013.

Trade-Ideas: ViroPharma (VPHM) Is Today's Post-Market Laggard Stock

Trade-Ideas: ViroPharma (VPHM) Is Today's Post-Market Laggard Stock

Trade-Ideas LLC identified ViroPharma (VPHM) as a post-market laggard candidate

First Week Of September 21st Options Trading For ViroPharma (VPHM)

First Week Of September 21st Options Trading For ViroPharma (VPHM)

Investors in ViroPharma Inc. saw new options begin trading this week, for the September 21st expiration.